HATTR-PN

Clinical trials for HATTR-PN explained in plain language.

Never miss a new study

Get alerted when new HATTR-PN trials appear

Sign up with your email to follow new studies for HATTR-PN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug trial aims to halt rare, debilitating nerve disease

Disease control Recruiting now

This study is testing an investigational drug called nucresiran for people with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), a rare disease that causes progressive nerve damage. The goal is to see if nucresiran can slow or stop the worsening of nerve funct…

Matched conditions: HATTR-PN

Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control

Last updated Mar 20, 2026 14:47 UTC

HATTR-PN

Get alerted when new HATTR-PN trials appear

New drug trial aims to halt rare, debilitating nerve disease